Business context and reporting period
The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing identified as Gyre Therapeutics, Inc. Investors should confirm the issuer and filing before relying on this summary. Catalyst was a pre-commercial biopharmaceutical company; it reported no approved products or product-sales revenue and said it was exploring strategic alternatives to monetize its assets.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| License and collaboration revenue | $0.8 million | $1.5 million; down 46% |
| Research and development expense | $9.7 million | $17.0 million; down 43% |
| General and administrative expense | $5.0 million | $5.4 million; down 8% |
| Operating loss | $14.7 million | $22.4 million |
| Net loss | $14.5 million | $22.4 million |
| Basic and diluted net loss per share | $0.46 | $0.79 |
| Cash used in operating activities | $12.1 million | $24.4 million |
Revenue was reimbursement for Biogen collaboration research services; collaboration costs were approximately equal to revenue, so this activity generated little gross contribution. Cash and cash equivalents were $34.8 million at March 31, down from $44.3 million at year-end; short-term investments were zero, versus $2.5 million at year-end. Total assets were $40.3 million, total liabilities $13.2 million, and accumulated deficit $417.2 million. The filing reports no debt balance. No operating margin is stated; the company remained loss-making.
Material changes versus the prior period
- Net loss narrowed by $7.9 million, primarily as R&D expense fell by $7.3 million, including lower hemophilia-related spending following program discontinuations. This reflects reduced activity and costs, not improved revenue generation.
- Biogen gave notice in March to terminate its agreement, effective May 2022, and returned full rights to CB 2782-PEG in March. The agreement had provided the quarter’s collaboration revenue.
- In March, the company terminated 22 employees; five full-time employees remained. It recorded about $1.0 million of related severance and other charges, expected to be paid in Q2.
- Cash used in operations decreased year over year, while Q1 2021 cash flows included $49.3 million of net proceeds from a public offering; Q1 2022 had no comparable offering proceeds.
Outlook, risks, contingencies, and unusual items
- Management said available cash was expected to fund requirements for at least 12 months from the filing date, while cautioning that assumptions could prove incorrect. Additional funding could come from financing, asset sales, licensing, collaborations, or partnerships; availability and terms are uncertain and equity financing could dilute shareholders.
- The company said it had ceased R&D activities and expected aggregate R&D expense to be minimal during the next year while pursuing strategic opportunities. It engaged Perella Weinberg Partners in February to assist with monetizing assets.
- Other programs had been discontinued: MarzAA trials were halted, and the company was exploring a sale or license of MarzAA and DalcA. The filing also describes CB 4332 and other complement assets; their future development depends on strategic opportunities.
- Q1 included a $0.2 million gain from extinguishment of a liability. The company also recorded approximately $1.0 million in current-quarter workforce-reduction charges. A prior-period $3.8 million write-off of prepaid MarzAA manufacturing costs was recorded in 2021.
- Manufacturing and clinical commitments include a CFI study agreement with payments up to $6.5 million, subject to termination terms, and $0.1 million remaining on CB 4332 manufacturing work orders. No ISU Abxis milestones had been met as of quarter-end; the agreement provides for up to $19.5 million if milestones are achieved.
- COVID-19 could disrupt clinical trials, suppliers, manufacturing, and logistics. The filing identifies an unremediated material weakness in internal control over financial reporting relating to review and GAAP accounting for employee retention bonuses. Management said remediation efforts were underway; disclosure controls were deemed ineffective as of March 31.
Important facts for investors to verify
- Confirm that Catalyst Biosciences—not Gyre Therapeutics—is the intended issuer and that this Q1 2022 filing is the intended source.
- Check the effective date and consequences of Biogen’s termination, and whether the returned CB 2782-PEG rights led to a sale, license, or other strategic transaction.
- Assess actual cash burn after the workforce reduction and program wind-down, versus management’s stated 12-month liquidity estimate.
- Track the company’s remaining workforce, liabilities, contractual commitments, and progress in remediating the material weakness.
- Verify whether any financing, asset monetization, or partnership occurred and its impact on liquidity and shareholder dilution.